Table 3.
Patient Characteristics According to Ras Mutation or Wild-Type
| Ras Mutant N = 14 |
Non-Ras Mutant N = 24 |
P Value | |
|---|---|---|---|
| Median age (years) | 58.5 | 39.5 | .220 |
| Range | (28-68) | (25-76) | |
| Mean age | 53.7 | 47.1 | |
| FIGO stage | |||
| I | 3 (21.4%) | 1 (4.2%) | .105 |
| II | - | - | |
| III | 7 (50%) | 21 (87.5%) | |
| IV | 4 (28.6%) | 2 (8.3%) | |
| Surgery | |||
| Primary debulking | 7 (50%) | 18 (75%) | .163 |
| Interval debulking | 7 (50%) | 6 (25%) | |
| Residual tumor | |||
| R0 | 11 (78.6%) | 22 (91.7%) | .337 |
| R > 1 | 3 (21.4%) | 2 (8.3%) | |
| R0-1 | - | - | |
| Association of borderline component | 6 (42.9%) | 12 (50%) | .745 |
| Initial systemic treatment | |||
| Platinum-based chemo | 13 (92.9%) | 24 (100%) | .368 |
| Hormonal treatment | 1 (7.1%) | - | - |
| Bilateral | 9 (64.3%) | 19 (79.2%) | .217 |
| Unilateral | 5 (35.7%) | 3 (12.5%) | |
| Unknown | - | 2 (8.3%) | |
| Lymph node involvement | |||
| Yes | 6 (42.9%) | 9 (37.5%) | |
| No | 8 (57.1%) | 15 (62.5%) | |
| Ascites | |||
| Yes | 6 (42.9%) | 4 (16.7%) | 1.000 |
| No | 8 (57.1%) | 19 (79.2%) | |
| Unknown | - | 1 (4.2%) |